GenKyoTex (Switzerland) a clinical-stage pharmaceutical company focused on the treatment of complications of diabetes including diabetic nephropathy, closed a $20.8M Series C financing. Participants include Edmond de Rothschild Investment Partners, Vesalius Biocapital, MP Healthcare Venture Management and Specialized European Fund for Therapeutic Innovation.

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $2.6M Series D financing, bringing the total round to $42.6M. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, [...]

Covagen (Switzerland) a development-stage biopharmaceutical company focused on a protein scaffold platform (Fynomer) for therapeutic use, closed a $6.5M Series A financing. Participants include Seroba Kernel Life Sciences, Edmond de Rothschild Investment Partners, MP Healthcare Venture Management, Novartis Venture Fund and Ventech.

SuperSonic Imagine (France) a commercial-stage medical device thearagnotic imaging company focused on the ultrasound visualization and measurement of tissue elasticity, closed a $25M Series C financing. Participants include Edmond de Rothschild Investment Partners, Auriga Partners, Credit Agricole Private Equity, NBGI Ventures, BioAm, Wellington Partners Venture Capital and iXO Private Equity.

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $40M Series D financing. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt [...]

Genticel (France) a clinical-stage biopharmaceutical company focused on therapeutic vaccines for the prevention of cervical cancer in HPV infected women, closed a $17.7M Series C financing. Participants include AGF Private Equity, Institut Régional de Développement Industriel, Amundi Private Equity Funds, InnoBio Fund and Edmond de Rothschild Investment Partners.

Regado Biosciences (Basking Ridge, NJ) a clinical-stage biopharmaceutical company with an aptamer platform drug-antidote pairing system focused upon the anticoagulant market, closed a $40M Series D financing. Participants include Edmond de Rothschild Investment Partners, Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

PDC Biotech (Austria) a preclinical-stage biopharmaceutical company focused upon women’s health preterm labor and primary dysmenorrhea, closed a $5.5M Series A financing. Participants include MIG Verwaltungs and Edmond de Rothschild Investment Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Probiodrug (Germany) a clinical-stage small molecule biopharmaceutical company focused upon Alzheimer’s and inflammation diseases, closed a $54M Series B financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Science Partners, Biogen Idec New Ventures, HBM Bioventures and TVM Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb